Literature DB >> 17971785

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Russell A Wilke1, Debbie W Lin, Dan M Roden, Paul B Watkins, David Flockhart, Issam Zineh, Kathleen M Giacomini, Ronald M Krauss.   

Abstract

Serious adverse drug reactions (SADRs) are a major cause of morbidity and mortality worldwide. Some SADRs may be predictable, based upon a drug's pharmacodynamic and pharmacokinetic properties. Many, however, appear to be idiosyncratic. Genetic factors may underlie susceptibility to SADRs and the identification of predisposing genotypes may improve patient management through the prospective selection of appropriate candidates. Here we discuss three specific SADRs with an emphasis on genetic risk factors. These SADRs, selected based on wide-sweeping clinical interest, are drug-induced liver injury, statin-induced myotoxicity and drug-induced long QT and torsades de pointes. Key challenges for the discovery of predictive risk alleles for these SADRs are also considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17971785      PMCID: PMC2763923          DOI: 10.1038/nrd2423

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  136 in total

1.  An underrecognized challenge in evaluating postmarketing drug safety.

Authors:  Dan M Roden
Journal:  Circulation       Date:  2005-01-25       Impact factor: 29.690

2.  Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study.

Authors:  Arne Pfeufer; Shapour Jalilzadeh; Siegfried Perz; Jakob C Mueller; Martin Hinterseer; Thomas Illig; Mahmut Akyol; Cornelia Huth; Andreas Schöpfer-Wendels; Bernhard Kuch; Gerhard Steinbeck; Rolf Holle; Michael Näbauer; H-Erich Wichmann; Thomas Meitinger; Stefan Kääb
Journal:  Circ Res       Date:  2005-03-03       Impact factor: 17.367

3.  Incidence of drug-induced liver injury in medical inpatients.

Authors:  Yvonne Meier; Marzia Cavallaro; Malgorzata Roos; Christiane Pauli-Magnus; Gerd Folkers; Peter J Meier; Karin Fattinger
Journal:  Eur J Clin Pharmacol       Date:  2005-02-23       Impact factor: 2.953

4.  Idiosyncratic liver injury: challenges and approaches.

Authors:  Paul B Watkins
Journal:  Toxicol Pathol       Date:  2005       Impact factor: 1.902

5.  Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.

Authors:  Russell A Wilke; Jason H Moore; James K Burmester
Journal:  Pharmacogenet Genomics       Date:  2005-06       Impact factor: 2.089

Review 6.  Idiosyncratic drug hepatotoxicity.

Authors:  Neil Kaplowitz
Journal:  Nat Rev Drug Discov       Date:  2005-06       Impact factor: 84.694

7.  A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy.

Authors:  Kaori Morimoto; Tomoharu Oishi; Shiro Ueda; Madoka Ueda; Masakiyo Hosokawa; Kan Chiba
Journal:  Drug Metab Pharmacokinet       Date:  2004-12       Impact factor: 3.614

Review 8.  Drug-induced hepatotoxicity: 2005.

Authors:  Willis C Maddrey
Journal:  J Clin Gastroenterol       Date:  2005-04       Impact factor: 3.062

Review 9.  Genetics of acquired long QT syndrome.

Authors:  Dan M Roden; Prakash C Viswanathan
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

10.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.

Authors: 
Journal:  Nature       Date:  2007-06-07       Impact factor: 49.962

View more
  108 in total

Review 1.  Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2010-06-10       Impact factor: 4.849

2.  Early human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics.

Authors:  K A Perkins; C Lerman
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

3.  Pharmacogenetics: implementing personalized medicine.

Authors:  Enrico Mini; Stefania Nobili
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

4.  The Dark Side of the Moon - the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management.

Authors:  Richard Greil
Journal:  Breast Care (Basel)       Date:  2009-06-26       Impact factor: 2.860

Review 5.  Genome-wide association studies in pharmacogenomics.

Authors:  Ann K Daly
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

Review 6.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 7.  Predicting risk of adverse drug reactions in older adults.

Authors:  Amanda Hanora Lavan; Paul Gallagher
Journal:  Ther Adv Drug Saf       Date:  2016-02

Review 8.  Electronic medical records as a tool in clinical pharmacology: opportunities and challenges.

Authors:  D M Roden; H Xu; J C Denny; R A Wilke
Journal:  Clin Pharmacol Ther       Date:  2012-06       Impact factor: 6.875

9.  Genealogical analysis as a new approach for the investigation of drug intolerance heritability.

Authors:  Marc Tremblay; Tarek Bouhali; Daniel Gaudet; Diane Brisson
Journal:  Eur J Hum Genet       Date:  2013-11-27       Impact factor: 4.246

10.  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.

Authors:  Naga Chalasani; Robert J Fontana; Herbert L Bonkovsky; Paul B Watkins; Timothy Davern; Jose Serrano; Hongqiu Yang; James Rochon
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.